AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$ICLR

McCague Eugene Pacelli sold $570K of ICLR

McCague Eugene Pacelli sold 3,255 shares of ICON PLC (ICLR) at $175.00 ($0.57M total) on 2026-09-17.

Original reporting
SEC EDGAR · McCague Eugene Pacelli
Published Sep 18, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The disclosed sale is modest in size and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

Director's remaining holdings still represent a sizable stake, and no other insiders have sold recently.

Relevance 5/10Novelty 5/10Timing: filed today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

Director Eugene Pacelli sold 3,255 shares of ICON PLC for $569,625 in an open‑market transaction filed today.

Expected impact

Potential slight downward pressure on ICLR price in the short term.

Evidence & confidence

The sale represents a small fraction of the director's remaining holdings and is under $1M, limiting material impact.

Market effects

Sector

Minimal effect on the healthcare services sector.

Regional

No significant regional impact.

Global

Limited relevance to global markets.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    ICON PLC

    UK‑based clinical research organization.

  • Individual
    Eugene Pacelli

    Director of ICON PLC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICLR insider trading history →

Related articles

JUL 29
$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

finanznachrichten.de3 min
JUL 29
$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

SEC EDGAR 6-K2 min
JUL 28
$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

investing.com3 min
JUL 28
$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.

rttnews.com2 min